Sun Pharmaceutical Industries Limited has announced its 34th Annual General Meeting (AGM), scheduled for Friday, July 31, 2026, at 4:00 p.m. IST via Video Conferencing. The company has also fixed Tuesday, July 07, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹5 per equity share for the financial year 2025-26. Payment of the dividend, if approved, will be made on or before Friday, August 07, 2026.
34th Annual General Meeting Details
Sun Pharmaceutical Industries Limited will convene its 34th Annual General Meeting (AGM) on Friday, July 31, 2026. The meeting is scheduled to commence at 4:00 p.m. Indian Standard Time (IST) and will be conducted through Video Conferencing (VC). The official Notice of the AGM, along with the Annual Report for the financial year 2025–26, will be distributed to shareholders in due course, adhering to all statutory requirements.
Shareholder Information Update
Shareholders are strongly advised to ensure their latest contact details, including email addresses and physical addresses, are up-to-date. For shareholders holding shares in dematerialized form, updates should be made with their respective Depository Participants. For those holding shares in physical form, updates should be provided to the Company’s Registrar and Transfer Agent (RTA). This ensures timely delivery of important documents such as the Annual Report and AGM Notice, and facilitates the smooth credit of dividends.
Record Date and Final Dividend for FY 2025-26
The company has set Tuesday, July 07, 2026, as the Record Date. This date will be used to determine which shareholders are entitled to receive the final dividend for the financial year 2025–26. A final dividend of ₹5/- (Rupees Five only) per equity share has been proposed. Subject to approval by shareholders at the AGM, the payment of this dividend is expected to be made on or before Friday, August 07, 2026.
Tax Deducted at Source (TDS) on Dividend
Dividend payments are subject to Tax Deducted at Source (TDS) at the applicable rates. Shareholders are encouraged to consult the TDS guidance and document submission process available on the company’s website, www.sunpharma.com, or via the provided QR code. Any requisite documents to enable the application of appropriate TDS rates should be submitted by shareholders on or before Tuesday, July 07, 2026.
Issued By:
Sun Pharmaceutical Industries Limited
(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983
Source: BSE
